TSX Exchange Symbol: RVX
CALGARY, May 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on May 8, 2008 at 9:00 pm MDT to provide a year-end update on both the science and the business aspects of the Company. Following the presentation there will be a live question and answer session.
The webcast can be accessed at the following link:
http://services.choruscall.com/links/resverlogix0800508.html or on
Resverlogix's website at: http://www.resverlogix.com.
Participants can also dial in for the conference call:
Dial information is as follows:
International Dial In: 1 604 638 5340
North America Toll Free: 1 800 319 4610
The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved